Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Journal Information
Full Title: Br J Haematol
Abbreviation: Br J Haematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST The authors have no competing interests. Yael C. Cohen received honoraria from GSK, unrelated to this research. All other authors have no conflict of interests to declare."
Funding Disclosure
Evidence found in paper:
"The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel‐Aviv Sourasky Medical Center, for his technical support preparing the figures."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025